Introductıon

Explor Target Antitumor Ther

ETAT

Exploration of Targeted Anti-tumor Therapy

2692-3114

Open Exploration Publishing

10.37349/etat.2026.1002396

1002396

Review

Precision oncology in the treatment of patients with bone sarcomas: an up-to-date narrative review

Yarar

Sude

Investigation Writing—original draft ¹

https://orcid.org/0000-0002-6631-2053

Tsagkozis

Panagiotis

Conceptualization Writing—review & editing Validation Supervision ² ³ ^* Piccaluga

Pier Paolo

Academic Editor IRCCS Azienda Ospedaliero-Universitaria di Bologna, Italy

¹Istanbul Faculty of Medicine, Istanbul University, Istanbul 34452, Turkey ²Department of Molecular Medicine and Surgery, Karolinska Institutet, 171 76 Stockholm, Sweden ³Karolinska University Hospital, 171 64 Solna, Sweden

^*Correspondence: Panagiotis Tsagkozis, Department of Molecular Medicine and Surgery, Karolinska Institutet, 171 76 Stockholm, Sweden. panagiotis.tsagkozis@ki.se

2026

09 08 2026

1002396

20 03 2026 17 06 2026

This is an Open Access article licensed under a Creative Commons Attribution 4.0 International License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, sharing, adaptation, distribution and reproduction in any medium or format, for any purpose, even commercially, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

Primary bone sarcomas are rare and biologically heterogeneous malignancies for which therapeutic progress remains limited, particularly in metastatic and recurrent disease. Advances in genomic and molecular profiling have revealed substantial inter- and intratumoral heterogeneity across the major subtypes, including osteosarcoma, Ewing sarcoma and chondrosarcoma, challenging conventional histology-driven treatment strategies. Precision medicine approaches are being increasingly explored to better capture this biological complexity and guide individualized therapeutic decision-making. This review examines emerging precision oncology strategies in bone sarcomas, including molecular diagnostics, targeted therapeutic approaches, three-dimensional functional modeling systems, and liquid biopsy technologies for dynamic disease monitoring. Together, these platforms provide biologically informed frameworks for patient-specific treatment and longitudinal assessment of tumor evolution. However, clinical implementation remains limited by genomic complexity, small patient cohorts, and methodological variability across experimental platforms. The integration of multi-layered precision models combining genomic stratification, functional drug sensitivity testing and circulating biomarker monitoring may enable more adaptive and individualized management strategies. Such approaches have the potential to improve therapeutic selection and ultimately advance outcomes for patients with primary bone sarcomas.

bone sarcoma functional assays drug sensitivity precision oncology

Introductıon

Bone sarcomas are rare and heterogeneous malignant mesenchymal tumors arising from osseous tissue, accounting for approximately 0.2% of all malignant tumors [1]. Despite their low incidence, these tumors represent a major clinical challenge due to their aggressive biological behavior, early metastatic potential, and disproportionate impact on children, adolescents, and young adults [2]. Osteosarcoma, Ewing sarcoma, and chondrosarcoma constitute the most common primary bone sarcoma subtypes, each characterized by distinct epidemiological patterns, molecular drivers, and clinical trajectories [1].

Historically, bone sarcomas have been classified and managed primarily according to histopathological features and anatomical location. However, accumulating genomic and epigenetic evidence demonstrates that these tumors comprise biologically stratified entities rather than a single disease spectrum [3]. Large-scale clinical genomic profiling studies have revealed subtype-specific alterations, recurrent gene rearrangements, and potentially actionable molecular events across sarcoma subtypes [4]. In parallel, DNA methylation-based classification and other molecular diagnostic tools have improved tumor categorization in cases where morphology alone is insufficient [5]. These findings underscore the profound inter- and intratumoral heterogeneity that underlies clinical variability and therapeutic resistance.

Despite advances in molecular characterization, therapeutic progress has been comparatively modest. Multimodal treatment combining surgery, chemotherapy, and radiotherapy has improved outcomes in localized disease, yet survival rates for metastatic, recurrent, or refractory bone sarcomas remain unsatisfactory [6]. Moreover, current treatment paradigms largely rely on standardized regimens that do not systematically incorporate molecular stratification or predictive biomarkers.

In parallel with advances in molecular profiling, digital health technologies and Internet of Things (IoT)-based systems are increasingly being integrated into oncologic practice. In musculoskeletal oncology, IoT-enabled platforms may support real-time imaging integration, surgical navigation, wearable postoperative monitoring, and remote multidisciplinary collaboration, potentially contributing to more individualized management strategies for patients with bone sarcomas [7].

The expanding understanding of bone sarcoma biology has therefore increased interest in precision medicine approaches aimed at integrating genomic profiling, dynamic disease monitoring, and patient-specific therapeutic strategies.

Current treatment of bone sarcomas

Current management of bone sarcomas relies on multimodal treatment integrating surgery, systemic chemotherapy, and radiotherapy. Despite subtype-specific differences, therapeutic strategies remain primarily guided by histopathological classification rather than molecular stratification [8].

Surgical resection with negative margins represents the cornerstone of curative treatment for localized bone sarcomas [9]. Limb-sparing procedures are now feasible in most patients, although metastatic burden, tumor biology, and resectability continue to influence long-term outcomes [10, 11]. Radiotherapy is mainly incorporated in Ewing sarcoma because of its relative radiosensitivity, whereas osteosarcoma and conventional chondrosarcoma demonstrate relative radioresistance [12]. Systemic multi-agent chemotherapy constitutes a central component of treatment for osteosarcoma and Ewing sarcoma, whereas its role in conventional chondrosarcoma remains limited, as summarized in Table 1 [13].

Table 1

Current standard treatment strategies and major limitations across primary bone sarcoma subtypes.

Subtype	Surgery	Chemotherapy regimen	Radiotherapy	Major limitations
Osteosarcoma	Wide resection, limb-sparing	MAP (HD-MTX, doxorubicin, cisplatin) ± ifosfamide	Limited role	Plateau in survival, chemoresistance
Ewing sarcoma	Surgery ± RT	VDC/IE	Frequently used	Poor metastatic outcomes
Chondrosarcoma	Primary treatment	Limited efficacy	Limited role	Chemoresistance

MAP: methotrexate–doxorubicin–cisplatin; HD-MTX: high-dose methotrexate; VDC/IE: vincristine–doxorubicin–cyclophosphamide/ifosfamide–etoposide; RT: radiotherapy.

In osteosarcoma, the introduction of methotrexate–doxorubicin–cisplatin (MAP)-based chemotherapy (high-dose methotrexate, doxorubicin, and cisplatin) significantly improved survival in localized disease; however, outcomes for metastatic or recurrent disease have remained largely unchanged over recent decades [14]. Attempts to intensify postoperative regimens have not consistently improved survival outcomes [15]. Current osteosarcoma treatment strategies remain largely standardized despite increasing evidence that genomic variability influences therapeutic response and progression-free survival [16]. Ewing sarcoma is commonly treated with dose-intensive vincristine–doxorubicin–cyclophosphamide/ifosfamide–etoposide (VDC/IE)-based chemotherapy combined with surgery and/or radiotherapy, achieving improved outcomes in localized disease but limited survival in relapsed or metastatic settings [17]. Conventional chondrosarcoma demonstrates intrinsic resistance to cytotoxic chemotherapy, leaving surgery as the primary treatment modality in most patients [18].

Other oncological treatments

The limited improvement in outcomes for metastatic and recurrent primary bone sarcomas has accelerated interest in targeted therapies as a core pillar of precision medicine. However, unlike many epithelial cancers in which high-frequency, druggable driver mutations enable relatively direct biomarker-to-therapy matching, bone sarcomas are frequently characterized either by complex genomic instability (osteosarcoma), fusion-driven transcriptional programs with low mutational burden (Ewing sarcoma), or subtype-dependent metabolic/epigenetic alterations with limited systemic options (chondrosarcoma). Consequently, targeted treatment development has largely centered on pathway-level dependencies, tumor-microenvironment signaling, and rational combinations rather than single-driver inhibition, and the clinical impact of targeted agents has been variable and often modest [19, 20].

In osteosarcoma, the absence of a dominant recurrent oncogenic driver has shifted therapeutic development toward targeting multi-kinase signaling, angiogenesis, and downstream growth pathways [21]. Clinically, multi-kinase inhibitors and pathway-directed agents have been investigated as strategies to suppress proliferative and pro-metastatic signaling in this genomically unstable disease [22]. Patient-derived xenograft (PDX) models further illustrate the translational rationale for these approaches, identifying regimens with activity in drug-resistant osteosarcoma, including regorafenib monotherapy, irinotecan-based combinations, and multi-agent strategies incorporating kinase and mTOR-pathway inhibition [23, 24]. These observations highlight a central principle of precision medicine in osteosarcoma: therapeutic vulnerabilities often emerge from pathway-level network dependencies rather than from single genomic alterations. This may explain why apparent “actionable” alterations identified through molecular profiling do not consistently translate into durable clinical benefit without complementary functional validation.

Ewing sarcoma provides a distinct paradigm for targeted therapy development. Although it is defined by EWSR1–ETS (EWS RNA-binding protein 1–ETS transcription factor fusion family) fusions, the disease-defining transcription factor remains difficult to target directly, and the overall scarcity of additional recurrent mutations limits classical mutation-driven precision oncology [25, 26]. As a result, translational efforts have focused on downstream signaling and epigenetic maintenance of the fusion-driven state. Ewing-targeted strategies have focused on IGF1R signaling, although the field has been constrained by the lack of currently recruiting trials and by the need for predictive biomarkers to identify responders. In parallel, developmental pathways and epigenetic modulators have emerged as major targets given the centrality of epigenetic dysregulation in fusion-driven sarcomas. Preclinical and early clinical efforts have explored HDAC inhibition, EZH2 targeting, BET inhibition, and LSD1 inhibition; notably, LSD1 inhibitors have progressed into phase I clinical evaluation, and preclinical data suggest that combinatorial epigenetic targeting may enhance activity compared with monotherapy [27–29]. Beyond epigenetic drugs, surface targets such as CD99 have been proposed as antibody-directed approaches, illustrating an alternative precision logic based on lineage-associated cell-surface dependencies rather than mutational drivers [25, 30]. Together, these strategies exemplify how precision medicine in Ewing sarcoma often relies on identifying pathways that sustain fusion-mediated transcription or mediate microenvironmental crosstalk, rather than targeting a high-frequency kinase mutation.

Chondrosarcoma remains one of the most challenging major bone sarcoma subtypes from a systemic therapy perspective, largely due to its intrinsic resistance to conventional cytotoxic chemotherapy and, in many cases, limited sensitivity to radiotherapy [31]. These features have motivated the development of molecularly informed strategies focused on recurrent metabolic and developmental pathway alterations. Mutations in IDH1 and IDH2 represent a central molecular axis in many chondrosarcomas, providing a biologically coherent rationale for mutant-IDH inhibition as a targeted therapeutic strategy [32, 33]. In addition, several signaling pathways have been proposed as potential therapeutic targets, including Hedgehog signaling, mTOR signaling, SRC/AKT pathway activity, and receptor tyrosine kinase alterations such as IGF1R and KIT amplification in specific subsets [18, 34]. While these approaches represent conceptually strong precision-medicine strategies, clinical benefit has frequently been limited or heterogeneous. This observation aligns with the broader view that chondrosarcoma comprises biologically diverse entities in which molecular stratification may be necessary but not sufficient to ensure therapeutic response.

Tyrosine kinase inhibitors (TKIs) and anti-angiogenic strategies

TKIs represent one of the most clinically advanced targeted therapy approaches in recurrent and unresectable bone sarcomas. Their rationale is based on the involvement of multiple receptor tyrosine kinases, including VEGFR, PDGFR, FGFR, KIT, RET, MET, AXL, and IGF1R, in angiogenesis, tumor proliferation, metastatic progression, and microenvironmental signaling. Because osteosarcoma and Ewing sarcoma rarely depend on a single dominant druggable driver, newer multi-receptor TKIs may be more clinically relevant than highly selective single-target agents. Recent reviews emphasize that anti-angiogenic multi-RTK inhibitors combine VEGFR blockade with simultaneous inhibition of additional pathways such as PDGFR, FGFR, KIT, RET, MET, or AXL, providing a rational strategy for biologically heterogeneous tumors [35].

In osteosarcoma, the strongest clinical evidence has emerged for regorafenib and cabozantinib. Two randomized phase II studies showed that regorafenib improved progression-free survival in recurrent or metastatic osteosarcoma compared with placebo, although no clear overall survival benefit was demonstrated [36, 37]. Cabozantinib has also shown encouraging activity in heavily pretreated osteosarcoma, with reported partial responses and disease control in a clinically meaningful subset of patients [38]. Other anti-angiogenic TKIs, including sorafenib, apatinib, anlotinib, lenvatinib, and pazopanib, have demonstrated varying degrees of disease stabilization or response in phase II, retrospective, or early clinical studies.

Despite these advances, the benefit of TKIs in osteosarcoma remains limited by acquired resistance, modest durability of response, toxicity, and the lack of validated predictive biomarkers. This explains why most studies show improvements in progression-free survival rather than overall survival [39]. Current evidence therefore suggests that TKIs are unlikely to serve as durable single-agent solutions in osteosarcoma. Instead, their future role may depend on biomarker-guided patient selection and rational combinations with chemotherapy, mTOR or MEK pathway inhibition, and immune checkpoint blockade [40, 41].

In Ewing sarcoma, the evidence base is less mature, but regorafenib and cabozantinib have demonstrated antitumor activity in phase II settings [38, 42, 43]. Cabozantinib produced objective responses and disease control in both Ewing sarcoma and osteosarcoma cohorts, while regorafenib also showed clinical activity in advanced Ewing sarcoma [38]. Anlotinib combined with chemotherapy has shown particularly notable response rates in early studies, although randomized comparisons are still needed to define the independent contribution of the TKI component [44, 45].

Overall, anti-angiogenic multi-RTK inhibitors represent one of the most promising therapeutic directions in advanced bone sarcomas. However, their current clinical value lies mainly in temporary disease control rather than durable remission. Future trials should prioritize molecular response biomarkers, earlier integration in selected patients, rational combination strategies, and toxicity-conscious dosing schedules to improve the therapeutic index of this drug class.

PARP inhibition and DNA damage response-targeted therapies

Poly(ADP-ribose) polymerase (PARP) inhibition has emerged as a promising DNA damage response-targeted therapeutic strategy in primary bone sarcomas, particularly osteosarcoma and Ewing sarcoma. Interest in this approach has been driven by increasing recognition of homologous recombination deficiency, genomic instability, and defective DNA repair signaling within these tumors. In osteosarcoma, genomic and epigenomic analyses have identified mutational signatures and chromosomal instability patterns resembling BRCA-deficient malignancies, leading to the concept of “BRCAness” in subsets of osteosarcoma [46]. These findings provide a biological rationale for exploiting synthetic lethality through PARP inhibition.

Despite this rationale, the therapeutic role of PARP inhibitors in osteosarcoma remains incompletely defined. Preclinical studies demonstrated that osteosarcoma cell lines with homologous recombination deficiency-associated molecular features may exhibit sensitivity to PARP inhibition, particularly when combined with DNA-damaging chemotherapy. Talazoparib combined with temozolomide showed synergistic induction of apoptosis and suppression of clonogenic survival in BRCAness-associated osteosarcoma models [47]. Similarly, olaparib combined with doxorubicin enhanced antitumor activity in vitro and in vivo, supporting the concept that PARP inhibition may potentiate chemotherapy-induced DNA damage in osteosarcoma [48]. However, broader chemosensitivity analyses have demonstrated substantial biological heterogeneity among osteosarcoma models, with inconsistent PARP inhibitor responsiveness despite genomic features suggestive of BRCAness [49]. Consequently, although PARP inhibition represents a biologically compelling strategy, its clinical application in osteosarcoma currently remains investigational, and validated predictive biomarkers are still lacking.

In Ewing sarcoma, the rationale for PARP inhibition appears stronger because of the direct interaction between EWS–FLI1 fusion signaling and PARP1-mediated DNA repair pathways. Early mechanistic studies demonstrated that EWS fusion proteins interact with PARP1 and promote dependence on PARP-associated transcriptional and DNA damage response mechanisms [50]. Subsequent translational studies further showed that PARP inhibition may enhance sensitivity to chemotherapy and radiotherapy through amplification of DNA damage and impaired repair capacity. Combination approaches involving PARP inhibitors with trabectedin, temozolomide, irinotecan, or radiation therapy have demonstrated synergistic antitumor activity in preclinical Ewing sarcoma models and PDXs [51, 52]. Recent work combining talazoparib, irinotecan, and radiation therapy further demonstrated prolonged survival and reduced tumor burden in orthotopic Ewing sarcoma xenograft models, supporting the potential role of PARP-based radiosensitization strategies in refractory disease settings [52].

Although these findings position PARP inhibition among the most biologically promising precision oncology strategies in bone sarcomas, several challenges remain. Clinical responses have been variable, acquired resistance mechanisms are incompletely understood, and durable benefit in prospective clinical trials has not yet been firmly established. Current research therefore increasingly focuses on biomarker-guided patient selection, identification of homologous recombination deficiency signatures, and rational combination strategies integrating PARP inhibitors with chemotherapy, radiotherapy, or other targeted agents.

Limitations of the current paradigm

Despite aggressive multimodal therapy, outcomes for metastatic, recurrent, and treatment-resistant bone sarcomas remain poor. Current treatment strategies are largely histology-driven and fail to adequately account for the substantial genomic and molecular heterogeneity observed across bone sarcoma subtypes [53]. In addition, chemoresistance, cumulative toxicity, and limited ability to predict therapeutic response continue to restrict clinical progress.

These limitations underscore the need for precision oncology approaches integrating molecular profiling, dynamic disease monitoring, and patient-specific therapeutic selection into routine clinical practice [54].

Precision medicine strategies in bone sarcomas Biological and molecular landscape of bone sarcomas

Bone sarcomas are biologically heterogeneous malignancies characterized by substantial genomic and molecular diversity. Large-scale profiling studies have identified subtype-specific alterations across osteosarcoma, Ewing sarcoma, and chondrosarcoma, demonstrating that histopathological classification alone insufficiently captures tumor biology and therapeutic vulnerability [55]. This molecular heterogeneity contributes to treatment resistance, disease progression, and variable clinical outcomes, while also providing the biological rationale for precision oncology approaches in bone sarcomas [56].

Bone sarcoma subtypes exhibit distinct genomic architectures that influence therapeutic strategies. Osteosarcoma is characterized by extensive chromosomal instability and widespread structural alterations involving pathways such as TP53 and RB1, contributing to marked intratumoral heterogeneity and variable treatment response [57, 58]. In contrast, Ewing sarcoma is primarily driven by recurrent EWSR1–ETS fusion proteins, most commonly EWSR1–FLI1, which promote oncogenesis through transcriptional and epigenetic dysregulation despite a relatively low mutational burden [59, 60]. Chondrosarcoma frequently harbors IDH1 and IDH2 mutations associated with metabolic and epigenetic alterations, although biological behavior varies substantially across subtypes [61].

Collectively, these findings highlight that bone sarcomas represent molecularly distinct diseases rather than a single clinical entity, supporting the development of biologically informed and subtype-specific therapeutic strategies.

Molecular diagnostics and genomic stratification

Molecular profiling has increasingly redefined primary bone sarcomas as biologically heterogeneous diseases rather than a single histology-driven spectrum. Clinically deployed next-generation sequencing (NGS) can redefine diagnosis, identify subtype-defining alterations, and detect potentially actionable molecular events, supporting its role as a central component of precision oncology [4, 62]. However, clinically actionable mutations remain relatively uncommon in many bone sarcomas, and the therapeutic relevance of genomic findings is often context-dependent, requiring complementary functional validation [63].

The precision oncology landscape differs substantially across bone sarcoma subtypes, as shown in Figure 1 and Table 2. Osteosarcoma is characterized by complex genomic architecture with extensive chromosomal instability, structural rearrangements, and copy-number alterations rather than recurrent targetable driver mutations [64, 65]. This complexity contributes to marked intratumoral heterogeneity and variable therapeutic response, limiting the effectiveness of single-target strategies [66]. Comprehensive profiling studies have identified multiple pathway-level abnormalities in refractory osteosarcoma; however, matched targeted therapies have frequently produced limited clinical benefit, highlighting the gap between molecular actionability and therapeutic efficacy [67]. Emerging approaches therefore increasingly focus on pathway-level dependencies, resistance biology, and regulatory signaling networks rather than isolated genomic alterations [68, 69]. Pharmacogenomic variability and regulatory mechanisms such as non-coding RNAs have also been implicated in treatment response and therapeutic resistance, particularly through pathways including Wnt/β-catenin signaling [70, 71].

Figure 1

Molecular profiling workflow and representative genomic alterations in major bone sarcoma subtypes. Created in BioRender. Tsagkozis, P. (2026) https://BioRender.com/02lutz3.

Table 2

Molecular characteristics and precision oncology implications across major bone sarcoma subtypes.

Subtype	Dominant genomic architecture	Highest-yield profiling targets	Primary precision output	Main limitation
Osteosarcoma	Complex-karyotype; chromosomal instability	Copy-number alterations, structural variants, pathway-state inference	Biological risk stratification; candidate targets often pathway-level	Actionability is diffuse; matched therapy benefit inconsistent
Ewing sarcoma	Fusion-driven (EWSR1–ETS); low mutation burden	Fusion identification/breakpoint assays; recurrent events (e.g., STAG2/CDKN2A)	Diagnostic confirmation/refinement; monitoring-amenable biomarkers	Few recurrent druggable point mutations; biomarker validation variable
Chondrosarcoma	Subtype-dependent; metabolic/epigenetic axis common	IDH1/2 status; genomic instability signatures (e.g., LOH burden); transcriptomic state	Molecular subgrouping beyond grade; trial stratification	Clinical translation of subgrouping still limited

EWSR1–ETS: EWS RNA-binding protein 1–ETS transcription factor fusion family; STAG2: stromal antigen 2; CDKN2A: cyclin dependent kinase inhibitor 2A; IDH1/2: isocitrate dehydrogenase 1 and 2; LOH: loss of heterozygosity.

In contrast, Ewing sarcoma is a fusion-driven malignancy primarily defined by EWSR1–ETS rearrangements, most commonly EWSR1–FLI1 [59]. Compared with osteosarcoma, Ewing sarcoma exhibits a relatively low mutational burden, shifting precision strategies toward fusion characterization and downstream signaling dependencies rather than mutation-based targeting [72, 73]. Molecular profiling additionally improves diagnostic accuracy and clinical trial stratification by identifying alternative fusion subtypes and biologically distinct transcriptional programs [74, 75]. However, many proposed biomarkers remain inconsistently validated across cohorts, highlighting the need for prospective validation before routine clinical implementation [76]. Recent studies further suggest that microenvironmental signaling networks and receptor-kinase pathways, including VEGFR2, MET, and AXL, may represent therapeutically relevant targets in Ewing sarcoma [77–79].

Chondrosarcoma demonstrates a distinct molecular landscape frequently associated with IDH1 and IDH2 mutations and epigenetic dysregulation [80]. However, emerging genomic and transcriptomic studies indicate that IDH status alone does not fully capture the biological heterogeneity of the disease [81–83]. Integrated molecular stratification approaches incorporating genomic instability patterns and expression-defined cellular states may therefore provide improved biological classification and future therapeutic guidance.

Collectively, molecular diagnostics and genomic stratification provide an essential foundation for precision medicine in bone sarcomas, although genomic profiling alone is often insufficient to predict therapeutic response. Increasingly, integrated precision oncology frameworks aim to combine genomic characterization with functional validation, molecular monitoring, and subtype-specific therapeutic targeting.

Targeted therapies Adoptive cellular treatment

Adoptive cellular therapies are emerging as an important next-generation precision oncology strategy in bone sarcomas, particularly for relapsed or treatment-refractory disease. These approaches include chimeric antigen receptor T-cell (CAR-T) therapy, T-cell receptor-engineered therapies (TCR-T), and NK-cell-based immunotherapy. Unlike immune checkpoint blockade, adoptive cellular therapies directly redirect immune effector cells toward tumor-associated antigens and may therefore overcome some of the immune resistance mechanisms observed in bone sarcomas [84].

In osteosarcoma, several tumor-associated antigens have been investigated as potential CAR-T targets, including B7-H3, GD2, HER2, and LRRC15 [85]. Among these, B7-H3 has emerged as one of the most promising candidates because of its frequent overexpression and association with metastatic progression and poor prognosis. Preclinical studies demonstrated significant antitumor activity of B7-H3-directed CAR-T cells in osteosarcoma models, including pulmonary metastatic disease. HER2-directed CAR-T therapy has likewise shown early clinical feasibility in sarcomas, although therapeutic responses remain heterogeneous [86, 87]. More recently, LRRC15-targeted CAR-T cells demonstrated encouraging preclinical antitumor activity in osteosarcoma models, supporting continued investigation of stromal-associated therapeutic targets [88].

TCR-engineered therapies are also being explored in sarcomas, particularly against cancer-testis antigens such as NY-ESO-1, MAGE-family antigens, and PRAME. Early clinical studies in synovial sarcoma demonstrated therapeutic activity of NY-ESO-1-directed TCR-engineered lymphocytes, supporting the broader rationale for adoptive TCR-based therapies in mesenchymal malignancies. Similar approaches are currently under investigation in osteosarcoma and Ewing sarcoma, although clinical data remain limited [89]. Compared with CAR-T approaches, TCR-engineered therapies may provide advantages in tumors with heterogeneous or low surface-antigen expression because they recognize intracellular antigens presented through HLA molecules.

In Ewing sarcoma, GD2- and VEGFR2-directed CAR-T strategies have demonstrated preclinical antitumor activity, particularly when combined with approaches targeting the immunosuppressive tumor microenvironment [90, 91]. Cellular therapy development in chondrosarcoma remains less advanced; however, recent studies suggest that B7-H3-directed CAR-T cells and epigenetic sensitization strategies may represent promising future therapeutic approaches, particularly in dedifferentiated subtypes resistant to conventional therapies [92].

Beyond CAR-T and TCR-T therapies, NK-cell-based adoptive immunotherapy is also being explored in pediatric and adolescent bone sarcomas because of its potential for MHC-independent tumor killing and lower risk of graft-versus-host disease [89]. Nevertheless, despite encouraging translational findings, most adoptive cellular therapy approaches in bone sarcomas remain in preclinical or early-phase clinical development. Current research increasingly focuses on biomarker-guided target selection, improvement of immune-cell trafficking and persistence, and rational combination strategies designed to overcome the immunosuppressive tumor microenvironment.

Immunotherapy

In parallel with subtype-specific pathway targeting, immune-based strategies are increasingly incorporated into precision oncology frameworks for bone sarcomas. Several studies have shown that bone sarcomas express immune checkpoint molecules such as PD-L1, PD-L2, and B7-H3, providing a biological rationale for checkpoint blockade and immune-directed clinical trials [93, 94]. However, review literature from the immunotherapy era emphasizes that bone sarcomas frequently exhibit immunosuppressive tumor microenvironments and heterogeneous checkpoint expression patterns across subtypes. These features likely contribute to inconsistent clinical responses and highlight the need for biomarker-guided patient selection and rational combination approaches. In this context, immunotherapy in bone sarcomas represents a precision challenge analogous to kinase targeting: the key question is not simply whether a target exists, but whether the tumor–host immune context is permissive for therapeutic response [95, 96].

Clinical responses to immune checkpoint inhibitors in bone sarcomas have generally remained limited. Early-phase studies investigating PD-1 and PD-L1 inhibitors, including pembrolizumab and nivolumab, demonstrated relatively low objective response rates in unselected osteosarcoma and Ewing sarcoma populations [71, 72]. These findings likely reflect the low tumor mutational burden, heterogeneous immune infiltration, and highly immunosuppressive tumor microenvironment characteristic of many bone sarcomas [69, 70]. Consequently, current research increasingly focuses on combination strategies integrating checkpoint blockade with anti-angiogenic therapies, radiotherapy, chemotherapy, or adoptive cellular therapies in an effort to enhance immune activation and improve therapeutic responsiveness [95].

Collectively, targeted therapies in bone sarcomas illustrate both the promise and the constraints of precision medicine in rare, heterogeneous mesenchymal malignancies. Across subtypes, therapeutic benefit appears highly context-dependent and often requires multi-layer molecular stratification—including genomic architecture, pathway state, and microenvironmental signaling [97]. Increasingly, functional validation strategies are also being incorporated to identify patients most likely to benefit from targeted interventions. These challenges provide a strong rationale for integrating targeted therapy development with dynamic monitoring approaches such as liquid biopsy and with patient-derived functional platforms, including organoids and PDOX models, which may help bridge the persistent gap between molecular “actionability” and clinically meaningful clinical response.

Metabolic targeting

Metabolic reprogramming has emerged as an important therapeutic vulnerability in chondrosarcoma, particularly in high-grade and dedifferentiated subtypes that remain largely resistant to conventional chemotherapy and radiotherapy [98]. Among the most clinically relevant alterations are mutations in isocitrate dehydrogenase 1 and 2 (IDH1/2), which are frequently identified in conventional and dedifferentiated chondrosarcomas and contribute to tumor progression through production of the oncometabolite D-2-hydroxyglutarate (2-HG) [99, 100].

These findings provided the rationale for the development of IDH-targeted therapies in chondrosarcoma. In a phase I study involving patients with advanced IDH1-mutant chondrosarcoma, the IDH1 inhibitor ivosidenib demonstrated a favorable safety profile and prolonged disease stabilization in a subset of patients, supporting the feasibility of metabolism-directed precision therapy in molecularly selected populations [101]. Although objective responses remain limited, these early clinical findings highlight the therapeutic relevance of metabolic targeting strategies in chondrosarcoma.

Additional metabolic pathways including PI3K-AKT-mTOR signaling, hypoxia-associated pathways, and glutamine metabolism have also emerged as potential therapeutic targets [102]. Experimental studies demonstrated that mTOR inhibition suppresses metabolic activity and tumor growth in chondrosarcoma models, supporting mTOR signaling as a potential pro-survival metabolic pathway [103]. Consequently, current research increasingly focuses on combination approaches integrating metabolic inhibition with epigenetic therapies, anti-angiogenic agents, or immunotherapy.

Overall, metabolic targeting represents one of the most promising emerging precision oncology strategies for advanced chondrosarcoma. However, most approaches remain at the preclinical or early translational stage, and further studies are required to identify predictive biomarkers and optimize combination-based therapeutic strategies.

Three-dimensional (3D) tumor models in precision medicine for bone sarcomas Conceptual rationale for 3D modeling

Bone sarcomas, including osteosarcoma, Ewing sarcoma, and chondrosarcoma, exhibit substantial genomic heterogeneity and complex interactions with the bone microenvironment, contributing to therapeutic resistance and variable clinical outcomes [56]. Although advances in molecular profiling have improved biological understanding, genotype-based stratification alone has not consistently translated into clinically actionable precision strategies, particularly in metastatic and recurrent disease.

One limitation of current precision approaches lies in the experimental systems used to evaluate therapeutic response. Conventional two-dimensional (2D) cultures inadequately reproduce the spatial organization and microenvironmental complexity of bone sarcomas, often limiting the predictive accuracy of preclinical drug testing [104]. Consequently, 3D tumor models have emerged as more physiologically relevant platforms capable of better recapitulating tumor heterogeneity, extracellular matrix interactions, and therapy resistance mechanisms [105]. Within a precision oncology framework, these systems may provide functional validation of therapeutic sensitivity beyond molecular profiling alone, and their main characteristics are shown in Table 3.

Table 3

Comparison of three-dimensional tumor modeling platforms in bone sarcoma precision medicine.

Model type	Biological fidelity	Main precision application	Key strength	Main limitation
Spheroids	Moderate (hypoxia and diffusion gradients)	Rapid drug screening	Simple and scalable	Limited matrix and niche realism
Scaffold-based systems	High (bone-mimetic stiffness and structure)	Local therapy + regenerative integration	Microenvironment realism	Manufacturing and clinical translation challenges
PDOs	High (tumor-intrinsic heterogeneity preserved)	Patient-specific drug response testing	Functional therapeutic prediction	Limited immune/stromal representation
PDX/PDOX models	Very high (in vivo architecture)	Regimen validation and resistance modeling	Whole-tumor fidelity	Cost, time, murine stroma
Biofabricated/Chip systems	Emerging high	Spatial and kinetic drug modeling	Architectural precision	Experimental stage

PDOs: patient-derived organoids; PDX: patient-derived xenograft.

Multicellular tumor spheroids

Multicellular tumor spheroids represent one of the simplest 3D tumor platforms and more closely reproduce the spatial organization and microenvironmental conditions of bone sarcomas compared with conventional monolayer cultures [106]. In bone sarcoma research, spheroid models have demonstrated increased chemoresistance and improved preservation of extracellular matrix interactions and invasion dynamics, highlighting their value for studying microenvironment-driven therapeutic resistance [107, 108].

From a precision medicine perspective, spheroids provide a relatively scalable and physiologically relevant platforms for preclinical drug testing. However, limitations including incomplete replication of bone-specific mechanical properties and limited stromal or immune representation restrict their ability to fully model the native tumor microenvironment [107, 108].

Scaffold-based 3D engineering

Scaffold-based 3D systems use engineered biomaterials to better reproduce the structural and mechanical properties of the bone microenvironment, which plays an important role in bone sarcoma progression [109]. Beyond improving biological realism, these platforms may also support localized drug delivery and regenerative reconstruction strategies [110].

Preclinical studies have demonstrated that scaffold-based systems can simultaneously promote tumor control and bone regeneration, highlighting their potential translational value in osteosarcoma management [111, 112]. However, despite these promising findings, scaffold platforms remain limited by technical complexity, regulatory challenges, and the lack of large-scale clinical validation [113].

Patient-derived organoids (PDOs) and PDX models

PDOs have emerged as one of the most clinically relevant 3D tumor platforms in bone sarcoma precision medicine, preserving patient-specific tumor architecture, genomic heterogeneity, and therapeutic response patterns [114].

In osteosarcoma, PDO-based chemosensitivity testing has demonstrated the ability to predict neoadjuvant chemotherapy response and correlate with long-term survival outcomes, supporting the use of organoids as functional biomarkers for individualized therapeutic selection [115]. Within a precision oncology framework, PDOs may therefore provide ex vivo validation of treatment sensitivity beyond molecular profiling alone.

However, organoid systems remain limited by variability in establishment success, incomplete immune and stromal representation, and lack of cross-center standardization [116].

PDX models provide additional in vivo biological fidelity by preserving tumor-microenvironment interactions [117]. In osteosarcoma, PDOX studies have identified potentially effective regimens for drug-resistant disease, including regorafenib- and irinotecan-based strategies, demonstrating that functional modeling may reveal therapeutic vulnerabilities not fully predicted by genomic profiling [118]. Nevertheless, broader clinical implementation remains limited by high cost, technical complexity, prolonged establishment times, and limited immune representation [119].

Emerging biofabrication platforms

Emerging biofabrication technologies, including 3D bioprinting and microfluidic tumor-on-chip systems, aim to recreate physiologically relevant tumor architecture and microenvironmental conditions in bone sarcomas [120, 121]. In parallel, 3D printing technologies are increasingly being explored for patient-specific surgical planning, reconstruction, and customized implant fabrication in complex bone sarcoma resections. Recent studies suggest that patient-specific 3D-printed models and guides may facilitate limb-salvage surgery, accurate tumor resection, and reconstruction in musculoskeletal oncology [91].

These platforms may improve the evaluation of therapeutic response, tumor heterogeneity, and metastatic behavior under dynamic experimental conditions. However, despite their translational potential, such systems remain largely preclinical and require further technical standardization and clinical validation before integration into routine precision oncology workflows [122].

Liquid biopsy

Liquid biopsy has emerged as a promising extension of precision medicine in primary bone sarcomas by enabling minimally invasive and longitudinal monitoring of tumor-derived biomarkers [123]. Unlike conventional tissue biopsy, which captures only a single anatomical region at one time point, liquid biopsy may better reflect tumor heterogeneity, clonal evolution, and treatment-related molecular changes [123, 124]. Circulating tumor DNA (ctDNA), circulating tumor RNA (ctRNA), circulating tumor cells (CTCs), and extracellular vesicles collectively provide dynamic insight into tumor biology and therapeutic response [125].

Among circulating analytes, ctDNA represents the most extensively investigated biomarker in bone sarcomas. In Ewing sarcoma, tumor-specific EWSR1–ETS fusion sequences enable highly sensitive plasma-based molecular monitoring, with ctDNA levels correlating with tumor burden, treatment response, and clinical outcomes [126, 127]. Persistence of detectable ctDNA following induction chemotherapy has additionally been associated with inferior survival outcomes, supporting potential applications in minimal residual disease (MRD) assessment and early relapse prediction [128]. These findings suggest that fusion-driven sarcomas may be particularly suitable for molecular monitoring approaches.

In contrast, liquid biopsy in osteosarcoma remains more challenging because of extensive genomic instability and the absence of recurrent driver alterations [129, 130]. Nevertheless, dynamic ctDNA changes may still provide clinically relevant information regarding treatment response and impending relapse, potentially offering a broader representation of tumor heterogeneity than localized tissue sampling alone [128].

The clinical role of liquid biopsy in chondrosarcoma remains less established. Although IDH1 and IDH2 mutations are recurrent in some subtypes, biomarker detectability and translational applicability appear more variable than in Ewing sarcoma and osteosarcoma [131].

Additional circulating biomarkers, including ctRNA, CTCs, and extracellular vesicles, may further contribute to molecular monitoring and characterization of metastatic behavior [132–136]. Nevertheless, detection platforms remain technically heterogeneous, and prospective validation in bone sarcoma cohorts is limited [137, 138].

Despite promising early findings, liquid biopsy in bone sarcomas remains an emerging field requiring larger prospective studies and assay standardization. Nevertheless, as precision oncology strategies evolve, liquid biopsy may serve as a valuable complement to tissue profiling, imaging, and functional modeling platforms by enabling real-time molecular monitoring and adaptive therapeutic stratification [123, 139]. The currently investigated liquid biopsy biomarkers, their principal clinical applications, and major limitations in bone sarcomas are summarized in Table 4.

Table 4

Liquid biopsy biomarkers and clinical applications in bone sarcomas.

ctDNA (fusion-based)	Ewing sarcoma	MRD detection, relapse prediction	Emerging–strong	Limited large validation
ctDNA (genomic instability)	Osteosarcoma	Response monitoring	Emerging	Variable sensitivity
ctRNA	Ewing sarcoma	Functional activity tracking	Early	RNA instability
CTCs	Metastatic disease	Biological characterization	Early	Low detection rate
Exosomal markers	Investigational	Microenvironment insight	Early	Standardization lacking

ctDNA: circulating tumor DNA; ctRNA: circulating tumor RNA; CTCs: circulating tumor cells; MRD: minimal residual disease.

Conclusions

Despite rapid advances in genomic profiling and experimental modeling, the clinical translation of precision medicine in primary bone sarcomas remains incomplete [140]. While molecular characterization has refined diagnostic classification and improved biological understanding, its integration into routine therapeutic decision-making remains limited.

A major barrier is the rarity of bone sarcomas, which restricts cohort sizes and complicates the design of biomarker-driven prospective trials [141, 142]. Most genomic, liquid biopsy, and functional modeling studies are derived from relatively small or retrospective cohorts, limiting statistical power and generalizability. In addition, the pronounced inter- and intratumoral heterogeneity observed in these malignancies, particularly in genomically unstable osteosarcoma, reduces the predictive value of single-time-point molecular assessments and contributes to therapeutic resistance [143].

Methodological variability further constrains clinical implementation. Differences in sequencing platforms, bioinformatic pipelines, ctDNA detection thresholds, and organoid establishment protocols hinder standardization and cross-study comparability. Moreover, certain precision platforms, such as PDX models, require timelines that may not align with the urgency of clinical decision-making in aggressive disease settings.

Future progress will likely depend on integrated, multi-layered frameworks rather than isolated modalities. Genomic stratification can define biological subtypes and candidate therapeutic targets; functional modeling platforms may validate drug sensitivity in patient-specific systems; and liquid biopsy approaches can enable longitudinal monitoring of clonal evolution and MRD. The coordinated application of these strategies, supported by multi-institutional collaboration and biomarker-driven clinical trials, represents a promising pathway toward clinically actionable precision oncology in bone sarcomas [142].

Ultimately, precision medicine in bone sarcomas should not be viewed as the pursuit of a single actionable mutation, but rather as an adaptive framework integrating molecular diagnostics, therapeutic targeting, and dynamic disease monitoring. Such an approach acknowledges the profound biological complexity of these malignancies and provides a pathway toward more individualized and biologically informed patient care.

Abbreviations

three-dimensional

CAR-T

chimeric antigen receptor T-cell

CTCs

circulating tumor cells

ctDNA

circulating tumor DNA

ctRNA

circulating tumor RNA

EWSR1–ETS

EWS RNA-binding protein 1–ETS transcription factor fusion family

IDH1/2

isocitrate dehydrogenase 1 and 2

IoT

Internet of Things

MRD

minimal residual disease

PARP

poly(ADP-ribose) polymerase

PDOs

patient-derived organoids

PDX

patient-derived xenograft

TCR-T

T-cell receptor-engineered therapies

TKIs

tyrosine kinase inhibitors

Declarations Author contributions

SY: Investigation, Writing—original draft. PT: Conceptualization, Writing—review & editing, Validation, Supervision. Both authors read and approved the submitted version.

Conflicts of interest

The authors declare no conflicts of interest.

Ethical approval

Not applicable.

Consent to participate

Not applicable.

Consent to publication

Not applicable.

Availability of data and materials

Not applicable.

Funding

Not applicable.

Publisher’s note

Open Exploration maintains a neutral stance on jurisdictional claims in published institutional affiliations and maps. All opinions expressed in this article are the personal views of the author(s) and do not represent the stance of the editorial team or the publisher.

Palmerini

Righi

Staals

Rare Primary Malignant Bone Sarcomas

Cancers (Basel) 2020 12

3092

10.3390/cancers12113092

33114111

PMC7690832

Reed

Hayashi

Wagner

Binitie

Steppan

Brohl

et al.

Treatment pathway of bone sarcoma in children, adolescents, and young adults

Cancer 2017 123 2206 18

10.1002/cncr.30589

28323337

PMC5485018

Lupo

Spector

O’Brien

Schiffman

Hettmer

Epidemiology of Bone and Soft Tissue Sarcomas

Arndt

CAS

Sarcomas of Bone and Soft Tissues in Children and Adolescents Pediatric Oncology. Cham

Springer

2021 pp. 1–16.

10.1007/978-3-030-51160-9_1

Gounder

Agaram

Trabucco

Robinson

Ferraro

Millis

et al.

Clinical genomic profiling in the management of patients with soft tissue and bone sarcoma

Nat Commun 2022 13

3406

10.1038/s41467-022-30496-0

35705558

PMC9200814

Khan

Kumar

R N

Chakma

Das

Sarcoma diagnosis by DNA methylation classifier: A systematic review, current status and future prospects

Pathol Res Pract 2024 263

155634

10.1016/j.prp.2024.155634

39383738

Bădilă

Rădulescu

Niculescu

Grumezescu

Rădulescu

Recent Advances in the Treatment of Bone Metastases and Primary Bone Tumors: An Up-to-Date Review

Cancers (Basel) 2021 13

4229

10.3390/cancers13164229

34439383

PMC8392383

Mulita

Verras

Anagnostopoulos

Kotis

A Smarter Health through the Internet of Surgical Things

Sensors (Basel) 2022 22

4577

10.3390/s22124577

35746359

PMC9231158

Gerrand

Amary

Anwar

Brennan

Dileo

Kalkat

et al.

UK guidelines for the management of bone sarcomas

Br J Cancer 2025 132 32 48

10.1038/s41416-024-02868-4

39550489

PMC11723950

Bläsius

Delbrück

Hildebrand

Hofmann

Surgical Treatment of Bone Sarcoma

Cancers (Basel) 2022 14

2694

10.3390/cancers14112694

35681674

PMC9179414

Moretti

Ashana

Lackman

Impact of close surgical margin on local recurrence and survival in osteosarcoma

Int Orthop 2012 36 131 7

10.1007/s00264-011-1230-x

21404025

PMC3251690

Smolle

Kogler

Andreou

Scheipl

Bergovec

Castellani

et al.

Prognostic Impact of Pulmonary Metastasectomy in Bone Sarcoma Patients: A Retrospective, Single-Centre Study

Cancers (Basel) 2023 15

1733

10.3390/cancers15061733

36980620

PMC10046382

Locquet

Brahmi

Blay

Dutour

Radiotherapy in bone sarcoma: the quest for better treatment option

BMC Cancer 2023 23

742

10.1186/s12885-023-11232-3

37563551

PMC10416357

Wagner

Livingston

Patel

Benjamin

Chemotherapy for Bone Sarcoma in Adults

J Oncol Pract 2016 12 208 16

10.1200/JOP.2015.009944

26962160

Isakoff

Bielack

Meltzer

Gorlick

Osteosarcoma: Current Treatment and a Collaborative Pathway to Success

J Clin Oncol 2015 33 3029 35

10.1200/JCO.2014.59.4895

26304877

PMC4979196

Marina

Smeland

Bielack

Bernstein

Jovic

Krailo

et al.

Comparison of MAPIE versus MAP in patients with a poor response to preoperative chemotherapy for newly diagnosed high-grade osteosarcoma (EURAMOS-1): an open-label, international, randomised controlled trial

Lancet Oncol 2016 17 1396 408

10.1016/S1470-2045(16)30214-5

27569442

PMC5052459

Gill

Gorlick

Advancing therapy for osteosarcoma

Nat Rev Clin Oncol 2021 18 609 24

10.1038/s41571-021-00519-8

34131316

Eaton

Claude

Indelicato

Vatner

Yeh

Schwarz

et al.

Ewing sarcoma

Pediatr Blood Cancer 2021 68 Suppl 2

e28355

10.1002/pbc.28355

33818887

MacDonald

Lin

Kuo

Tang

An update on current and future treatment options for chondrosarcoma

Expert Rev Anticancer Ther 2019 19 773 86

10.1080/14737140.2019.1659731

31462102

Heymann

Rédini

Targeted therapies for bone sarcomas

Bonekey Rep 2013 2

378

10.1038/bonekey.2013.112

24422100

PMC3817966

Miwa

Yamamoto

Hayashi

Takeuchi

Igarashi

Tsuchiya

Therapeutic Targets for Bone and Soft-Tissue Sarcomas

Int J Mol Sci 2019 20

170

10.3390/ijms20010170

30621224

PMC6337155

Liu

Huang

Liao

Rothzerg

Yao

et al.

Current research progress in targeted anti-angiogenesis therapy for osteosarcoma

Cell Prolif 2021 54

e13102

10.1111/cpr.13102

34309110

PMC8450128

Jin

Huang

Dong

Xiong

Wang

et al.

Research status and prospects of molecular pathological mechanisms and novel therapeutic targets of osteosarcoma: a systematic review

Front Oncol 2026 15

1665299

10.3389/fonc.2025.1665299

41640444

PMC12864143

Higuchi

Igarashi

Yamamoto

Hayashi

Kimura

Miwa

et al.

Osteosarcoma Patient-derived Orthotopic Xenograft (PDOX) Models Used to Identify Novel and Effective Therapeutics: A Review

Anticancer Res 2021 41 5865 71

10.21873/anticanres.15406

34848441

Shi

Innovative gene targeted treatments for osteosarcoma: a mini review of current clinical evidence and future prospects

Front Med (Lausanne) 2025 12

1699287

10.3389/fmed.2025.1699287

41346999

PMC12673487

Pishas

Lessnick

Recent advances in targeted therapy for Ewing sarcoma

F1000Res 2016 5 F1000 Faculty Rev 2077

10.12688/f1000research.8631.1

27635231

PMC5007751

Fayzullina

Tsibulnikov

Stempen

Schroeder

Kumar

Kharwar

et al.

Novel Targeted Therapeutic Strategies for Ewing Sarcoma

Cancers (Basel) 2022 14

1988

10.3390/cancers14081988

35454895

PMC9032664

Loganathan

Tang

Fleming

Guo

Borinstein

et al.

BET bromodomain inhibitors suppress EWS-FLI1-dependent transcription and the IGF1 autocrine mechanism in Ewing sarcoma

Oncotarget 2016 7 43504 17

10.18632/oncotarget.9762

27259270

PMC5190040

Welch

Kahen

Fridley

Brohl

Cubitt

Reed

Small molecule inhibition of lysine-specific demethylase 1 (LSD1) and histone deacetylase (HDAC) alone and in combination in Ewing sarcoma cell lines

PLoS One 2019 14

e0222228

10.1371/journal.pone.0222228

31550266

PMC6759167

Theisen

Pishas

Saund

Lessnick

Therapeutic opportunities in Ewing sarcoma: EWS-FLI inhibition via LSD1 targeting

Oncotarget 2016 7 17616 30

10.18632/oncotarget.7124

26848860

PMC4951237

Manara

Manferdini

Cristalli

Carrabotta

Santi

Feo A

et al.

Engagement of CD99 Activates Distinct Programs in Ewing Sarcoma and Macrophages

Cancer Immunol Res 2024 12 247 60

10.1158/2326-6066.CIR-23-0440

38051221

PMC10835215

Gazendam

Popovic

Parasu

Ghert

Chondrosarcoma: A Clinical Review

J Clin Med 2023 12

2506

10.3390/jcm12072506

37048590

PMC10095313

Walter

Knöll

Eysel

Quaas

Gaisendrees

Nißler

et al.

Molecular In-Depth Characterization of Chondrosarcoma for Current and Future Targeted Therapies

Cancers (Basel) 2023 15

2556

10.3390/cancers15092556

37174021

PMC10177611

Miwa

Yamamoto

Hayashi

Takeuchi

Igarashi

Tsuchiya

Therapeutic Targets and Emerging Treatments in Advanced Chondrosarcoma

Int J Mol Sci 2022 23

1096

10.3390/ijms23031096

35163019

PMC8834928

Polychronidou

Karavasilis

Pollack

Huang

Lee

Jones

Novel therapeutic approaches in chondrosarcoma

Future Oncol 2017 13 637 48

10.2217/fon-2016-0226

28133974

Fleuren

EDG

Vlenterie

van der Graaf

WTA

Recent advances on anti-angiogenic multi-receptor tyrosine kinase inhibitors in osteosarcoma and Ewing sarcoma

Front Oncol 2023 13

1013359

10.3389/fonc.2023.1013359

36994209

PMC10040783

Davis

Bolejack

Ryan

Ganjoo

Loggers

Chawla

et al.

Randomized Double-Blind Phase II Study of Regorafenib in Patients With Metastatic Osteosarcoma

J Clin Oncol 2019 37 1424 31

10.1200/JCO.18.02374

31013172

PMC7799443

Duffaud

Mir

Boudou-Rouquette

Piperno-Neumann

Penel

Bompas

et al. French Sarcoma Group

Efficacy and safety of regorafenib in adult patients with metastatic osteosarcoma: a non-comparative, randomised, double-blind, placebo-controlled, phase 2 study

Lancet Oncol 2019 20 120 33

10.1016/S1470-2045(18)30742-3

30477937

Italiano

Mir

Mathoulin-Pelissier

Penel

Piperno-Neumann

Bompas

et al.

Cabozantinib in patients with advanced Ewing sarcoma or osteosarcoma (CABONE): a multicentre, single-arm, phase 2 trial

Lancet Oncol 2020 21 446 55

10.1016/S1470-2045(19)30825-3

32078813

PMC8763616

Chen

Shi

Ren

Huang

Guo

Current progress and open challenges for applying tyrosine kinase inhibitors in osteosarcoma

Cell Death Discov 2022 8

488

10.1038/s41420-022-01252-6

36509754

PMC9744866

Giacchi

Pucci

Rucci

From Bench to Bedside: Advancements in Precision Oncology and Drug Discovery for Osteosarcoma

Cancers (Basel) 2026 18

561

10.3390/cancers18040561

41749815

PMC12939273

Albarrán

Villamayor

Chamorro

Rosero

Pozas

San

Román M

et al.

Receptor Tyrosine Kinase Inhibitors for the Treatment of Recurrent and Unresectable Bone Sarcomas

Int J Mol Sci 2022 23

13784

10.3390/ijms232213784

36430263

PMC9697271

Attia

Bolejack

Ganjoo

George

Agulnik

Rushing

et al.

A phase II trial of regorafenib in patients with advanced Ewing sarcoma and related tumors of soft tissue and bone: SARC024 trial results

Cancer Med 2023 12 1532 9

10.1002/cam4.5044

35950293

PMC9883574

Duffaud

Blay

Mir

Chevreau

Boudou

Rouquette P

Kalbacher

et al.

LBA68 Results of the randomized, placebo (PL)-controlled phase II study evaluating the efficacy and safety of regorafenib (REG) in patients (pts) with metastatic relapsed Ewing sarcoma (ES), on behalf of the French Sarcoma Group (FSG) and UNICANCER

Ann Oncol 2020 31

S1199

Xie

Sun

Liu

Tang

Yan

et al.

Anlotinib, Vincristine, and Irinotecan for Advanced Ewing Sarcoma After Failure of Standard Multimodal Therapy: A Two-Cohort, Phase Ib/II Trial

Oncologist 2021 26 e1256 62

10.1002/onco.13726

33611805

PMC8265337

Wang

Chu

Zhang

Wang

Yan

Yao

et al.

Safety and Efficacy of Chemotherapy Combined with Anlotinib Plus Anlotinib Maintenance in Chinese Patients with Advanced/Metastatic Soft Tissue Sarcoma

Onco Targets Ther 2020 13 1561 8

10.2147/OTT.S235349

32110053

PMC7038775

Barenboim

Kovac

Ameline

Jones

DTW

Witt

Bielack

et al.

DNA methylation-based classifier and gene expression signatures detect BRCAness in osteosarcoma

PLoS Comput Biol 2021 17

e1009562

10.1371/journal.pcbi.1009562

34762643

PMC8584788

Engert

Kovac

Baumhoer

Nathrath

Fulda

Osteosarcoma cells with genetic signatures of BRCAness are susceptible to the PARP inhibitor talazoparib alone or in combination with chemotherapeutics

Oncotarget 2017 8 48794 806

10.18632/oncotarget.10720

27447864

PMC5564725

Park

Bae

Kim

Moon

Park

et al.

The PARP inhibitor olaparib potentiates the effect of the DNA damaging agent doxorubicin in osteosarcoma

J Exp Clin Cancer Res 2018 37

107

10.1186/s13046-018-0772-9

29784019

PMC5963190

Holme

Gulati

Brough

Fleuren

EDG

Bajrami

Campbell

et al.

Chemosensitivity profiling of osteosarcoma tumour cell lines identifies a model of BRCAness

Sci Rep 2018 8

10614

10.1038/s41598-018-29043-z

30006631

PMC6045584

Brenner

Feng

Han

Patel

Goyal

Bou-Maroun

et al.

PARP-1 inhibition as a targeted strategy to treat Ewing’s sarcoma

Cancer Res 2012 72 1608 13

10.1158/0008-5472.CAN-11-3648

22287547

PMC3319786

Ordóñez

Amaral

Carcaboso

Herrero-Martín

del Carmen García-Macías

Sevillano

et al.

The PARP inhibitor olaparib enhances the sensitivity of Ewing sarcoma to trabectedin

Oncotarget 2015 6 18875 90

10.18632/oncotarget.4303

26056084

PMC4662461

Xie

Mellado-Lagarde

Blankenship

Ganguly

Twarog

Bianski

et al.

The Combination of PARP and Topoisomerase 1 Inhibitors Improves Radiation Therapy for Ewing Sarcoma

Cancer Sci 2025 116 1703 14

10.1111/cas.70042

40069935

PMC12127087

López-Fuentes

Clugston

Lee

Sayles

Sorensen

Pons

Ventura MV

et al.

Epigenetic and Transcriptional Programs Define Osteosarcoma Subtypes and Establish Targetable Vulnerabilities

Cancer Discov 2026 16 296 319

10.1158/2159-8290.CD-25-0237

41037662

PMC12877751

Yarber

Agulnik

Targeted therapies in bone sarcomas: current approach and future directions

Expert Opin Investig Drugs 2011 20 973 9

10.1517/13543784.2011.577064

21510829

Gaspar

Giannatale A

Geoerger

Redini

Corradini

Enz-Werle

et al.

Bone sarcomas: from biology to targeted therapies

Sarcoma 2012 2012

301975

10.1155/2012/301975

23226965

PMC3514839

Brown

Schiavone

Gouin

Heymann

Biology of Bone Sarcomas and New Therapeutic Developments

Calcif Tissue Int 2018 102 174 95

10.1007/s00223-017-0372-2

29238848

PMC5805807

Rickel

Fang

Tao

Molecular genetics of osteosarcoma

Bone 2017 102 69 79

10.1016/j.bone.2016.10.017

27760307

PMC5393957

Czarnecka

Synoradzki

Firlej

Bartnik

Sobczuk

Fiedorowicz

et al.

Molecular Biology of Osteosarcoma

Cancers (Basel) 2020 12

2130

10.3390/cancers12082130

32751922

PMC7463657

Grünewald

TGP

Cidre-Aranaz

Surdez

Tomazou

de Álava

Kovar

et al.

Ewing sarcoma

Nat Rev Dis Primers 2018 4

10.1038/s41572-018-0003-x

29977059

Showpnil

Selich-Anderson

Taslim

Boone

Crow

Theisen

et al.

EWS/FLI mediated reprogramming of 3D chromatin promotes an altered transcriptional state in Ewing sarcoma

Nucleic Acids Res 2022 50 9814 37

10.1093/nar/gkac747

36124657

PMC9508825

Cojocaru

Wilding

Engelman

Huang

Jones

Is the IDH Mutation a Good Target for Chondrosarcoma Treatment?

Current Molecular Biology Reports 2020 6 1 9

10.1007/s40610-020-00126-z

Gutiérrez-Jimeno

Alba-Pavón

Astigarraga

Imízcoz

Panizo-Morgado

García-Obregón

et al.

Clinical Value of NGS Genomic Studies for Clinical Management of Pediatric and Young Adult Bone Sarcomas

Cancers (Basel) 2021 13

5436

10.3390/cancers13215436

34771600

PMC8582364

Norberg

Movva

Role of genetic and molecular profiling in sarcomas

Curr Treat Options Oncol 2015 16

10.1007/s11864-015-0339-3

25939540

Scotlandi

Hattinger

Pellegrini

Gambarotti

Serra

Genomics and Therapeutic Vulnerabilities of Primary Bone Tumors

Cells 2020 9

968

10.3390/cells9040968

32295254

PMC7227002

Bai

Yang

Huang

et al.

Decoding osteosarcoma from heterogeneity to precision therapy

Discov Oncol 2025 17

192

10.1007/s12672-025-04256-7

41379383

PMC12858688

Southekal

Shakyawar

Bajpai

Elkholy

Manne

Mishra

et al.

Molecular Subtyping and Survival Analysis of Osteosarcoma Reveals Prognostic Biomarkers and Key Canonical Pathways

Cancers (Basel) 2023 15

2134

10.3390/cancers15072134

37046795

PMC10093233

Subbiah

Wagner

McGuire

Sarwari

Devarajan

Lewis

et al.

Personalized comprehensive molecular profiling of high risk osteosarcoma: Implications and limitations for precision medicine

Oncotarget 2015 6 40642 54

10.18632/oncotarget.5841

26510912

PMC4747358

Chen

Tian

Wang

Zheng

Kang

Harnessing multiomics to revolutionize understanding and management of osteosarcoma: A pathway to precision medicine (Review)

Int J Mol Med 2025 55

10.3892/ijmm.2025.5533

40242955

PMC12021390

Tang

Roberts

Cheng

Osteosarcoma Multi-Omics Landscape and Subtypes

Cancers (Basel) 2023 15

4970

10.3390/cancers15204970

37894336

PMC10605601

Hurkmans

EGE

Brand

ACAM

Verdonschot

JAJ

Loo DMWM

Coenen

MJH

Pharmacogenetics of chemotherapy treatment response and -toxicities in patients with osteosarcoma: a systematic review

BMC Cancer 2022 22

1326

10.1186/s12885-022-10434-5

36536332

PMC9761983

Fuloria

Yadav

Menon

Ali

Pant

Kaur

et al.

Targeting the Wnt/β-catenin cascade in osteosarcoma: The potential of ncRNAs as biomarkers and therapeutics

Pathol Res Pract 2024 259

155346

10.1016/j.prp.2024.155346

38781762

Anderson

Mutation Evolution and Genomic Patterns of Recurrence in Ewing Sarcoma and Leiomyosarcoma [dissertation] Canada

University of Toronto

2020

Crompton

Stewart

Taylor-Weiner

Alexe

Kurek

Calicchio

et al.

The genomic landscape of pediatric Ewing sarcoma

Cancer Discov 2014 4 1326 41

10.1158/2159-8290.CD-13-1037

25186949

Salguero-Aranda

Amaral

Olmedo-Pelayo

Diaz-Martin

Álava

Breakthrough Technologies Reshape the Ewing Sarcoma Molecular Landscape

Cells 2020 9

804

10.3390/cells9040804

32225029

PMC7226764

EWSR1 fusions: Ewing sarcoma and beyond

Cancer Cytopathol 2020 128 229 31

10.1002/cncy.22239

31995669

AlDoughaim

AlSuhebany

AlZahrani

AlQahtani

AlGhamdi

Badreldin

et al.

Cancer Biomarkers and Precision Oncology: A Review of Recent Trends and Innovations

Clin Med Insights Oncol 2024 18

11795549241298541

10.1177/11795549241298541

39559827

PMC11571259

Goodspeed

Bodlak

Duffy

Nelson-Taylor

Oike

Porfilio

et al.

Single-Cell RNA Sequencing of Ewing Sarcoma Tumors Demonstrates Transcriptional Heterogeneity and Clonal Evolution

Clin Cancer Res 2025 31 2010 23

10.1158/1078-0432.CCR-24-2040

40029262

PMC12081191

Gao

Qin

Feng

et al.

KC1036, a multi-kinase inhibitor with anti-angiogenic activity, can effectively suppress the tumor growth of Ewing sarcoma

Angiogenesis 2025 28

10.1007/s10456-025-10008-6

40965696

Knott

MML

Hölting

TLB

Ohmura

Kirchner

Cidre-Aranaz

Grünewald

TGP

Targeting the undruggable: exploiting neomorphic features of fusion oncoproteins in childhood sarcomas for innovative therapies

Cancer Metastasis Rev 2019 38 625 42

10.1007/s10555-019-09839-9

31970591

PMC6994515

Landuzzi

Ruzzi

Lollini

Scotlandi

Chondrosarcoma: New Molecular Insights, Challenges in Near-Patient Preclinical Modeling, and Therapeutic Approaches

Int J Mol Sci 2025 26

1542

10.3390/ijms26041542

40004005

PMC11855192

Setola

Microenvironment and prognostic factors in bone tumors: IDH mutations in chondrosarcoma [dissertation] Università di Bologna; 2022.

Deshmukh

Kelly

Tinoco

IDH1/2 Mutations in Cancer: Unifying Insights and Unlocking Therapeutic Potential for Chondrosarcoma

Target Oncol 2025 20 13 25

10.1007/s11523-024-01115-3

39546097

PMC12362722

Iacobescu

Corlatescu

Serban

Spiridonica

Costin

Cirstoiu

Genetics and Molecular Pathogenesis of the Chondrosarcoma: A Review of the Literature

Curr Issues Mol Biol 2024 46 12658 71

10.3390/cimb46110751

39590345

PMC11593320

Oliva-Ramirez

Milewski

Banks

Bailey

Moding

Lake

et al.

Future Directions and Priorities for Cellular Therapy in Sarcoma: A Report from the Strategic Advances in Sarcoma Science Cell Therapy Breakout

Cancers (Basel) 2025 17

3068

10.3390/cancers17183068

41008910

PMC12469009

Zhang

Shang

Current status and future challenges of CAR-T cell therapy for osteosarcoma

Front Immunol 2023 14

1290762

10.3389/fimmu.2023.1290762

38187386

PMC10766856

Phase I Study of B7H3 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young Adults [Internet]

[cited 2026 Aug 6]. Available from: https://www.medifind.com/articles/clinical-trial/227351331

Fradin

Charlson

Review of Adoptive Cellular Therapies for the Treatment of Sarcoma

Cancers (Basel) 2025 17

1302

10.3390/cancers17081302

40282478

PMC12026197

O’Reilly

Tuladhar

Nguyen

Sheppard

Koo

Chockley

et al.

LRRC15-CAR T Cells for the Treatment of Osteosarcoma

Clin Cancer Res 2026 32 1557 73

10.1158/1078-0432.CCR-24-2335

41627173

PMC13080327

Heymann

Schiavone

Heymann

Bone sarcomas in the immunotherapy era

Br J Pharmacol 2021 178 1955 72

10.1111/bph.14999

31975481

Englisch

Altvater

Kailayangiri

Hartmann

Rossig

VEGFR2 as a target for CAR T cell therapy of Ewing sarcoma

Pediatr Blood Cancer 2020 67

e28313

10.1002/pbc.28313

32729251

Dong

Beglinger

Krieg

Personalized 3D-printed guide in malignant bone tumor resection and following reconstruction - 17 cases in pelvic and extremities

Surg Oncol 2022 42

101733

10.1016/j.suronc.2022.101733

35397377

Osei-Hwedieh

Wang

Fan

Ferrone

Wang

et al.

HDAC inhibitor (SAHA) enhances B7-H3-specific CAR T cell cytotoxic efficacy against chondrosarcoma cells and prolongs survival in an orthotopic mouse model

Transl Oncol 2025 62

102538

10.1016/j.tranon.2025.102538

41037832

PMC12522712

Xie

Chen

Liang

Sun

et al.

Expression and Clinical Significance of Various Checkpoint Molecules in Advanced Osteosarcoma: Possibilities for Novel Immunotherapy

Orthop Surg 2023 15 829 38

10.1111/os.13620

36519392

PMC9977595

Nathenson

Conley

Sausville

Immunotherapy: A New (and Old) Approach to Treatment of Soft Tissue and Bone Sarcomas

Oncologist 2018 23 71 83

10.1634/theoncologist.2016-0025

28935774

PMC5759816

Panagi

Pilavaki

Constantinidou

Stylianopoulos

Immunotherapy in soft tissue and bone sarcoma: unraveling the barriers to effectiveness

Theranostics 2022 12 6106 29

10.7150/thno.72800

36168619

PMC9475460

Birdi

Jirovec

Cortés-Kaplan

Werier

Nessim

Diallo

et al.

Immunotherapy for sarcomas: new frontiers and unveiled opportunities

J Immunother Cancer 2021 9

e001580

10.1136/jitc-2020-001580

33526607

PMC7852926

Nakano

Challenges of Systemic Therapy Investigations for Bone Sarcomas

Int J Mol Sci 2022 23

3540

10.3390/ijms23073540

35408900

PMC8998654

Tlemsani

Larousserie

Percin S

Audard

Hadjadj

Chen

et al.

Biology and Management of High-Grade Chondrosarcoma: An Update on Targets and Treatment Options

Int J Mol Sci 2023 24

1361

10.3390/ijms24021361

36674874

PMC9862566

Zhu

Nafa

Agaram

Zehir

Benayed

Sadowska

et al.

Genomic Profiling Identifies Association of IDH1/IDH2 Mutation with Longer Relapse-Free and Metastasis-Free Survival in High-Grade Chondrosarcoma

Clin Cancer Res 2020 26 419 27

10.1158/1078-0432.CCR-18-4212

31615936

PMC6980683

100

Hirata

Sasaki

Cairns

Inoue

Puviindran

et al.

Mutant IDH is sufficient to initiate enchondromatosis in mice

Proc Natl Acad Sci U S A 2015 112 2829 34

10.1073/pnas.1424400112

25730874

PMC4352794

101

Tap

Villalobos

Cote

Burris

Janku

Mir

et al.

Phase I Study of the Mutant IDH1 Inhibitor Ivosidenib: Safety and Clinical Activity in Patients With Advanced Chondrosarcoma

J Clin Oncol 2020 38 1693 701

10.1200/JCO.19.02492

32208957

PMC7238491

102

Micaily

Roche

Ibrahim

Martinez-Outschoorn

Mallick

Metabolic Pathways and Targets in Chondrosarcoma

Front Oncol 2021 11

772263

10.3389/fonc.2021.772263

34938658

PMC8685273

103

Addie

de Jong

Alberti

Kruisselbrink

Que

Baelde

et al.

Exploration of the chondrosarcoma metabolome; the mTOR pathway as an important pro-survival pathway

J Bone Oncol 2019 15

100222

10.1016/j.jbo.2019.100222

30766792

PMC6360255

104

Molina

Chim

Barrios

Ludwig

Mikos

Modeling the Tumor Microenvironment and Pathogenic Signaling in Bone Sarcoma

Tissue Eng Part B Rev 2020 26 249 71

10.1089/ten.teb.2019.0302

32057288

PMC7310212

105

Gao

Shen

Hornicek

Duan

Three-dimensional (3D) culture in sarcoma research and the clinical significance

Biofabrication 2017 9

032003

10.1088/1758-5090/aa7fdb

28707624

106

Chaddad

Development of vascularized tumor spheroids mimicking the tumor environment: angiogenesis and hypoxia [dissertation] Université de Strasbourg; 2019.

107

Colella

Fazioli

Gallo

Chiara A

Apice

Ruosi

et al.

Sarcoma Spheroids and Organoids-Promising Tools in the Era of Personalized Medicine

Int J Mol Sci 2018 19

615

10.3390/ijms19020615

29466296

PMC5855837

108

Shah

D’Souza

GGM

Modeling Tumor Microenvironment Complexity In Vitro: Spheroids as Physiologically Relevant Tumor Models and Strategies for Their Analysis

Cells 2025 14

732

10.3390/cells14100732

40422235

PMC12110291

109

Koushik

Miller

Antunes

Bone Tissue Engineering Scaffolds: Function of Multi-Material Hierarchically Structured Scaffolds

Adv Healthc Mater 2023 12

e2202766

10.1002/adhm.202202766

36512599

PMC11468595

110

Huang

Zhou

Wang

Ren

et al.

Biomimetic structural design in 3D-printed scaffolds for bone tissue engineering

Mater Today Bio 2025 32

101664

10.1016/j.mtbio.2025.101664

40206144

PMC11979411

111

Jing

Yuan

Wang

Qin

Mao

et al.

Simvastatin/hydrogel-loaded 3D-printed titanium alloy scaffolds suppress osteosarcoma via TF/NOX2-associated ferroptosis while repairing bone defects

Bioact Mater 2023 33 223 41

10.1016/j.bioactmat.2023.11.001

38045570

PMC10689208

112

Rong

Xiao

Geng

Zhu

Mou

Ding

et al.

Sono-activable and biocatalytic 3D-printed scaffolds for intelligently sequential therapies in osteosarcoma eradication and defect regeneration

Nat Commun 2025 16

6150

10.1038/s41467-025-61377-x

40610512

PMC12229518

113

Alaribe

Manoto

Motaung

Scaffolds from biomaterials: advantages and limitations in bone and tissue engineering

Biologia 2016 71 353 66

10.1515/biolog-2016-0056

114

Tan

Guo

Patient-Derived Organoids as a Promising Tool for Multimodal Management of Sarcomas

Cancers (Basel) 2023 15

4339

10.3390/cancers15174339

37686615

PMC10486520

115

Nie

Wan

Zhou

Zhong

Yang

et al.

Personalized prediction of chemotherapy efficacy in osteosarcoma through patient-derived organoids: correlation with survival and tumor proliferation potential

J Exp Clin Cancer Res 2025 45

10.1186/s13046-025-03541-1

41382267

PMC12817525

116

Taurin

Alzahrani

Aloraibi

Ashi

Alharmi

Hassani

Patient-derived tumor organoids: A preclinical platform for personalized cancer therapy

Transl Oncol 2025 51

102226

10.1016/j.tranon.2024.102226

39622151

PMC11647637

117

Liu

Cai

Zhang

Shen

Han

Patient-derived xenograft models in cancer therapy: technologies and applications

Signal Transduct Target Ther 2023 8

160

10.1038/s41392-023-01419-2

37045827

PMC10097874

118

Higuchi

Hoffman

Tsuchiya

Yamamoto

Hayashi

Miwa

et al.

Osteosarcoma patient-derived orthotopic xenograft (PDOX) models for identification of novel and effective therapeutics

J Clin Oncol 2024 42

228

10.1200/jco.2024.42.23_suppl.228

119

Liu

Yang

Patient-derived xenograft models: Current status, challenges, and innovations in cancer research

Genes Dis 2025 12

101520

10.1016/j.gendis.2025.101520

40548062

PMC12179623

120

Liu

Ren

Ding

Wang

et al.

Engineering Osteosarcoma In Vitro: From Traditional Models to Biofabricated Platforms for Precision Medicine

ACS Omega 2025 10 55219 33

10.1021/acsomega.5c09120

41322649

PMC12658639

121

Chow

Wutami

Lucarelli

Choong

Duchi

Bella C

Creating In Vitro Three-Dimensional Tumor Models: A Guide for the Biofabrication of a Primary Osteosarcoma Model

Tissue Eng Part B Rev 2021 27 514 29

10.1089/ten.TEB.2020.0254

33138724

122

Domingues

Silva

Sanjuan‐Alberte

From spheroids to bioprinting: a literature review on biomanufacturing strategies of 3D in vitro osteosarcoma models

Adv Ther 2024 7

2400047

10.1002/adtp.202400047

123

Smolle

Seidel

Kashofer

Liegl-Atzwanger

Sadoghi

Müller

et al.

Precision medicine in diagnosis, prognosis, and disease monitoring of bone and soft tissue sarcomas using liquid biopsy: a systematic review

Arch Orthop Trauma Surg 2025 145

121

10.1007/s00402-024-05711-w

39797974

PMC11724793

124

Ucci

Rucci

Ponzetti

Liquid biopsies in primary and secondary bone cancers

Cancer Drug Resist 2022 5 541 59

10.20517/cdr.2022.17

36176757

PMC9511800

125

Seebacher

Hornicek

Xiao

Duan

Application of liquid biopsy in bone and soft tissue sarcomas: Present and future

Cancer Lett 2018 439 66 77

10.1016/j.canlet.2018.09.012

30223067

126

Allegretti

Casini

Mandoj

Benini

Alberti

Novello

et al.

Precision diagnostics of Ewing's sarcoma by liquid biopsy: circulating EWS-FLI1 fusion transcripts

Ther Adv Med Oncol 2018 10

1758835918774337

10.1177/1758835918774337

29899761

PMC5985603

127

Seidel

Kashofer

Moser

Thueringer

Liegl-Atzwanger

Leithner

et al.

Clinical implementation of plasma cell-free circulating tumor DNA quantification by digital droplet PCR for the monitoring of Ewing sarcoma in children and adolescents

Front Pediatr 2022 10

926405

10.3389/fped.2022.926405

36046479

PMC9420963

128

Liu

Zhang

Wang

Jian

et al.

Tumor-informed deep sequencing of ctDNA detects minimal residual disease and predicts relapse in osteosarcoma

EClinicalMedicine 2024 73

102697

10.1016/j.eclinm.2024.102697

39022798

PMC11252770

129

Shulman

Crompton

Using Liquid Biopsy in the Treatment of Patient with OS

Adv Exp Med Biol 2020 1257 95 105

10.1007/978-3-030-43032-0_9

32483734

130

van der Laan

van Houdt

van den Broek

Steeghs

van der Graaf

WTA

Liquid Biopsies in Sarcoma Clinical Practice: Where Do We Stand?

Biomedicines 2021 9

1315

10.3390/biomedicines9101315

34680432

PMC8533081

131

Aran

Devalle

Meohas

Heringer

Cunha

Caruso A

Pinheiro

Aguiar D

et al.

Osteosarcoma, chondrosarcoma and Ewing sarcoma: Clinical aspects, biomarker discovery and liquid biopsy

Crit Rev Oncol Hematol 2021 162

103340

10.1016/j.critrevonc.2021.103340

33894338

132

Aiyer

Kim

Collier

Pollock

Verschraegen

Stover

et al.

Unlocking the Potential of ctDNA in Sarcomas: A Review of Recent Advances

Cancers (Basel) 2025 17

1040

10.3390/cancers17061040

40149373

PMC11941651

133

Agnoletto

Caruso

Garofalo

Heterogeneous Circulating Tumor Cells in Sarcoma: Implication for Clinical Practice

Cancers (Basel) 2021 13

2189

10.3390/cancers13092189

34063272

PMC8124844

134

Tan

Wang

Min

The Roles of Exosomes in Metastasis of Sarcoma: From Biomarkers to Therapeutic Targets

Biomolecules 2023 13

456

10.3390/biom13030456

36979391

PMC10046038

135

Tamura

Yoshioka

Sakamoto

Ichikawa

Ochiya

Extracellular Vesicles in Bone Metastasis: Key Players in the Tumor Microenvironment and Promising Therapeutic Targets

Int J Mol Sci 2020 21

6680

10.3390/ijms21186680

32932657

PMC7555648

136

Jamil

Nawrooz

Bishoyi

Ballal

Singh

Krithiga

et al.

The therapeutic potential of exosomes in bone cancers: osteosarcoma, chondrosarcoma, and Ewing sarcoma

Invest New Drugs 2025 43 991 1012

10.1007/s10637-025-01551-6

40616723

137

Liao

Huang

Xiong

Sun

et al.

Extracellular vesicles in tumorigenesis, metastasis, chemotherapy resistance and intercellular communication in osteosarcoma

Bioengineered 2023 14 113 28

10.1080/21655979.2022.2161711

37377390

PMC10308873

138

The basic characteristics of extracellular vesicles and their potential application in bone sarcomas

J Nanobiotechnology 2021 19

277

10.1186/s12951-021-01028-7

34535153

PMC8447529

139

Wang

Fujiwara

Kurozumi

Ando

Ishimaru

Kondo

et al.

Advances in liquid biopsy for bone and soft-tissue sarcomas

Int J Clin Oncol 2025 30 1722 33

10.1007/s10147-025-02813-2

40679665

PMC12378253

140

Wallander

Öfverholm

Boye

Tsagkozis

Papakonstantinou

Lin

et al.

Sarcoma care in the era of precision medicine

J Intern Med 2023 294 690 707

10.1111/joim.13717

37643281

141

Czarnecka

Błoński

Chmiel

Rutkowski

Novel biomarkers in bone sarcomas—diagnosis, treatment selection, and clinical trials

Oncol Clin Pract 2025 21 154 65

10.5603/ocp.99779

142

Elshimy

Alkhatib

Atassi

Mohammad

Biomarker-Driven Approaches to Bone Metastases: From Molecular Mechanisms to Clinical Applications

Biomedicines 2025 13

1160

10.3390/biomedicines13051160

40426987

PMC12109438

143

Rajan

Zaccaria

Cannon

Cam

Gross

Raphael

et al.

Structurally Complex Osteosarcoma Genomes Exhibit Limited Heterogeneity within Individual Tumors and across Evolutionary Time

Cancer Res Commun 2023 3 564 75

10.1158/2767-9764.CRC-22-0348

37066022

PMC10093779